Use of antiretrovirals is widespread in Brazil, where more than 200,000 individuals are under treatment. Although general prevalence of primary antiretroviral resistance in Brazil is low, systematic sampling in large metropolitan areas has not being performed.
Findings
In the mid '90s, the Brazilian government took a major step in the fight against HIV/AIDS, making antiretrovirals available free to all infected individuals. In addition, a strong prevention programme was established to curb new infections. As a result of these strategies, AIDS-related mortality rates, which peaked in 1995/6, have declined continually, and the number of infected individuals stabilized at lower figures, which contradicts earlier worst-case predicted scenarios [1] .
However, given the sequential use of antiretroviral drugs in many patients at the beginning of this programme, the proportion of patients experiencing virologic failure is assumed to be high. In fact, one study, done in 2002 with patients on treatment in 1999/2000, showed that the median time for benefit of initial treatment was approximately 14 months among treatment-naïve patients [2] . Another study revealed that only 27.5% of patients maintained undetectable viral loads after one year of follow up. With the introduction of new drugs and more potent regimens, the level of efficacy of initial treatment increased substantially in Brazil.
HIV primary and secondary antiretroviral resistance is of major concern in a country such as Brazil, where there is widespread access to antiretroviral therapy. A study conducted in Brazil, which analyzed 2474 samples from patients on highly active antiretroviral treatment and who had virologic failure, showed that 95% presented with mutations related to antiretroviral resistance and of them, 21%, 45% and 34% presented resistance to one, two or three classes of antiretroviral drugs, respectively [3] .
In contrast, the frequency of primary resistance is much lower. Several independent surveys carried out in Brazilian cities, which analyzed drug-naïve populations selected from recently and chronically infected individuals, showed resistance rates varying from 1.4% to 8.3% [4, 5] . These numbers are not different from that observed in developed countries, where transmission of resistant viruses to one or more antiretroviral agent has been reported since 1993.
For instance, surveys conducted in developed countries during the past decade and targeting recent seroconverters have shown prevalence rates of 10% to 17% in France, 13% in German, 14% in the United Kingdom, 15% to 26% in North America, and 23% to 26% in Spain [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Recent surveys performed in the USA and Europe in comparable populations pointed out a slight increase in primary resistance prevalence, especially to non-nucleoside reverse transcriptase inhibitors (NNRTIs) [10] . A contrast to this picture is the low prevalence of primary drug-resistance mutation in South America and the Caribbean (<4%) [18] [19] [20] .
In order to monitor the transmission of drug-resistant strains and the subtype profile in Brazil, a National Network for Drug Resistance Surveillance (HIV-BResNet) in the chronically infected drug-naïve population was established in 2000. The first survey, done in 2001, showed an overall primary resistance rate of 6.6% with even distribution of NRTI, NNRTI and protease inhibitor (PI) resistance-related mutations [21] . Here, we describe the results of a new HIV-BResNet survey, conducted in 2007/8 on recently diagnosed HIV patients seeking treatment in AIDS clinics located in six major cities.
Threshold Survey developed by the World Health Organization (WHO), was utilized to compare primary resistance levels in patients in these cities. In this study, we targeted the four major country regions by selecting the six most populated state capitals (Sao Paulo, Rio de Janeiro, Salvador, Porto Alegre, Brasilia and Belem), accounting for more than 70% of the Brazilian HIV/AIDS epidemic and the majority of patients under antiretroviral treatment. The major clinical labs, where most recent diagnosed individuals have their first CD4+ T cell counts and viral loads determinations, were selected to conduct the patient selection, as well as genotypic analysis.
The inclusion criteria was homogeneous across the sites: participating individuals had to have received their HIV diagnosis in the past six months, not have been exposed to antiretroviral drugs for any reason, and had to be more than 18 years old. Individuals were selected to the study and were invited to read and sign informed consents. Samples were collected sequentially until 47 samples were reached and the questionnaire was completed. Samples were analyzed in the same order of inclusion in each site and were amplified and sequenced. This study received an institutional review board (IRB) approval (CONEP, IRB#9772), and informed consents were obtained from all participating individuals.
For genotypic analysis ViroSeq™ v2.0 (Celera Diagnostics, Alameda, California, USA) or TrueGene™ (Siemens Diagnostics, USA) were used. Mutation lists, as well as FASTA files generated by commercial software, were further evaluated according to published guidelines, which exclude common polymorphisms [22] . For subtype assignment, we first separated protease and reverse transcriptase coding regions and submitted the data to the Stanford HIVDR website. For quality assurance purposes, we re-sequenced 10% of samples in target sites..
The sample size and statistical approach from this survey was adapted from WHO's HIV drug resistance Threshold Survey (HIV DR THS) protocol [23] . Each city or region was treated as an independent sampling event, and a binomial sequential strategy was utilized: 47 consecutive HIV-positive specimens were collected and genotyped. The HIV drug resistance prevalence can be categorized into three different levels: low (<5%), moderate (5% to 10%), and high (>15%). The analysis can be stopped at the 34 initial specimens if the prevalence can be categorized as low (<5%, if n ≤ 1) or high (>15%, if n ≥ 6). If it is not met, an additional 13 specimens need to be genotyped to precisely calculate the prevalence categories.
We were able to study 223 individuals in six sites. Their clinical and demographic characteristics are depicted in Table 1 . The male:female ratio of our selected individuals was 0.95:1.05, and the average age was 36 years old. The average CD4+ T cell count was 577 cells/mm 3 , which suggests that the selected individuals were in the initial, asymptomatic stage of HIV infection.
We could successfully amplify and sequence 210 specimens, and found 17 (8.1%) isolates carrying primary drug-resistance mutations. Five, nine and four isolates showed mutations related to resistance to NRTIs, NNRTIs and PIs, respectively. The more prevalent were mutations related to NNRTI (K103N and Y188L/I), followed by NRTI and PI ( Table 2 ). The main PI mutation found was M46I (three individuals), followed by L90M (one individual). Interestingly, most PI mutations were found in Rio de Janeiro. There was a clear geographic trend in primary resistance. We found an intermediate level of transmitted resistance (5% to 15%) in Belem/Brasilia, Sao Paulo and Rio de Janeiro, contrasting with the other sites, where a lower level of transmitted resistance (<5%) was observed. Comparing this prevalence with the data obtained in the BResNet survey performed in 2002, it can be observed that the primary resistance in Brazil remains at a stable level, 6.6% in 2002 versus 8.1 in this latest BResNet survey. In support of this fact, lower levels of transmitted resistance have been detected in other surveys done in major cities, such as Sao Paulo, Rio de Janeiro and Porto Alegre [24] [25] [26] . On the other hand, other studies have demonstrated distinct levels of transmitted resistance in other geographic areas; for example, higher levels of primary resistance have been detected in Santos and Salvador [27, 28] . This study was not designed to evaluate the subtype distribution and the sample size was very limited in each of the sites sampled. However, we were able to observe that the subtype distribution found closely reflects previous data generated in Brazil. Subtype B was the more prevalent subtype found in all cities sampled (72%), except for Porto Alegre, where a large proportion of HIV-1 subtype C was observed (69%). This rate seems higher than the rate described in this city in HIV ResNet in 2002 (45%), suggesting an increase of this non-B subtype in this country region [21] .
Subtype F and several BF mosaics as well Unique Recombinant Forms (URFs) are the other major non-B strain spread throughout the country and corresponds to approximately 13% of the samples analyzed in our study. Interestingly, a CRF2 (A/G) isolate was found in Salvador Bahia, corroborating previous reports regarding the introduction of this west African strain in Brazil [29] .
Some studies have demonstrated that the time to obtain a viral load below the detection limit may be increased among individuals with primary resistance [30] . Regardless of high antiretroviral exposure levels and high rates of virologic antiretroviral failure found in Brazil, the general prevalence of primary antiretroviral resistance is still low. However, intermediate level of primary resistance was found in our four major cities, suggesting that more noticeable resistance is transmitted in these areas.
Of note, mutation K103N had a significant increase when the rate observed in 2002 (0.24%) is compared to the one found this study (3.3%; P < 0.001 chi-square). This fact probably reflects the widespread use of efavirenz in the first drug regimen in Brazil. Therefore, it is critical to start larger sampling surveys to better define the risk factors associated with transmission of primary resistance, as well as strengthen the prevention programmes targeting HIVpositive individuals in antiretroviral therapy. An increased prevalence of K103N can be a risk in the long run for the usage of NNRTI-based first-line antiretroviral regimens in Brazil.
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